HanAll's Partner HBM Announces IND Approval for Phase 2 of Batoclimab in CIDP in China
Date2021-09-02
Related Data
HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161 (batoclimab) & HL036 (tanfanercept) for the Chinese market, Harbour BioMed, has received IND approval for Phase 2 of batoclimab in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in China. The company is now pursuing 5 autoimmune diseases including myasthenia gravis (MG), grave’s ophthalmopathy (GO), adult immune thrombocytopenia (ITP), neuromyelitis optica spectrum disorder (NMOSD), and chronic inflammatory demyelinating polyneuropathy (CIDP) in the region.
For more information, please refer to the link below.
- HBM press release link: https://www.harbourbiomed.com/news/164.html